According to the Official Journal of the European Union, on January 19, 2024, the European Commission issued Regulation (EU) No. 2024/324, extending the approval period for 13 active substances such as fluoroamides, which will enter into force on the 20th day from the date of publication.

According to the regulations, the approval period for Mecoprop-P was extended until May 15, 2025.

The approval period for Flutolanil was extended to June 15, 2025.

The approval period for Pyraclostrobin was extended to September 15, 2025.

The approval period for Mepiquat was extended to 15 October 2025.

The approval period for Buprofezin was extended until December 15, 2025.

The approval period for Phosphane has been extended to March 15, 2026.

The approval period for Fluazinam was extended to April 15, 2026.

The approval period for Fluopyram was extended to June 30, 2026.

The approval period for Benzovindiflupyr was extended to August 2, 2026.

The approval period for Lambda-cyhalothrin and Metsulfuron-methyl has been extended to August 31, 2026.

The approval period for Bromuconazole was extended to April 30, 2027.

The approval period for Cyflufenamid has been extended until June 30, 2027.